Terns Pharmaceuticals, Inc. (NASDAQ: TERN) saw its stock rating downgraded to Neutral by analyst Andres Y. Maldonado of HC Wainwright & Co. on March 25, 2026. With a current share price of $50, the downgrade suggests that while the stock has potential upside, its performance may stabilize in the near term. Investors may wish to consider this rating shift in the context of TERN’s recent market developments and financial health.
Recent Price Action
In the days leading up to the analyst’s rating change, Terns Pharmaceuticals has exhibited noteworthy stock movements. Currently priced at $50, TERN’s share appreciated by approximately 5.55%, reflecting a change of $2.775. Recent trading volume surged to over 64 million shares, significantly exceeding its average volume of about 2.16 million, indicating heightened investor activity and potentially greater interest or uncertainty in the market. The stock’s volatility is further underscored by its 52-week high of $15.21 and a staggering 52-week low of $2094.1, demonstrating significant fluctuations in value. Despite these ups and downs, TERN has a beta of -0.288, suggesting an inverse relationship with market trends, which may appeal to certain risk-averse investors.
Short- and Long-Term Performance
Over the past month, Terns Pharmaceuticals has underperformed with a return of -12.86%. In contrast, the stock showcased remarkable quarterly momentum with a staggering 334.96% improvement, and a phenomenal yearly gain of 712.89%, which displays its extraordinary long-term performance amidst broader market conditions. This level of annual appreciation may pique the interest of growth-oriented investors. However, the volatility readings—6.45% for the week and 5.9% for the month—reveal a stock that could be susceptible to rapid price changes, reinforcing the need for caution in investment decisions.
Earnings Analysis
Terns Pharmaceuticals reported an earnings per share (EPS) of -$0.27, which comfortably surpassed the market’s estimate of -$0.30. This reflects a surprise factor of approximately -10%, though overall results remain in the realm of negative earnings. Comparatively, in the previous quarterly report dated August 5, 2025, TERN recorded an EPS of -$0.26 against an estimated -$0.28, again showing a negative surprise factor but consistent improvement. These earnings figures underline challenges the company faces, though the surpassing of estimates is a positive sign of greater financial predictability.
Analyst Consensus View
According to analyst sentiment over a 90-day period, Terns Pharmaceuticals holds a solitary rating from HC Wainwright with a consensus upgrade to Neutral, maintaining a consistent average price target of $53. Notably, there are currently no buy ratings, just one hold, and no sell recommendations, suggesting a cautious pause among analyst circles. This uniformity in ratings, coupled with the target price matching the current stock price, indicates limited immediate upward potential, even as the overall sentiment is not overwhelmingly negative.
Stock Grading or Fundamental View
The Stocks Telegraph Grade (ST Score) for Terns Pharmaceuticals stands at 53, indicating modest health and investment potential based on diverse financial and market analyses. This score signals neither strong conviction in the company’s growth trajectory nor severe underlying weaknesses, situating TERN as a middle-ground option for investors assessing risk and reward in peripheral biotech markets.
Conclusion
For investors interested in Terns Pharmaceuticals, the stock may suit those with a moderate risk appetite able to weather the inherent volatility associated with biotech equities. Although recent performance, particularly over the long term, has been impressive, the downgrade to Neutral and the lack of bullish analyst sentiment suggest that prospective investors should proceed cautiously. TERN embodies a potential growth opportunity, yet it carries risks associated with its unpredictable financial performance and market fluctuations. Careful observation will be pivotal for those choosing to watch this stock closely.